|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYP1B1 |
Gene summary for CYP1B1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYP1B1 | Gene ID | 1545 |
| Gene name | cytochrome P450 family 1 subfamily B member 1 | |
| Gene Alias | ASGD6 | |
| Cytomap | 2p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | Q16678 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1545 | CYP1B1 | P2T-E | Human | Esophagus | ESCC | 2.61e-02 | 1.78e-01 | 0.1177 |
| 1545 | CYP1B1 | P8T-E | Human | Esophagus | ESCC | 7.36e-05 | 3.07e-01 | 0.0889 |
| 1545 | CYP1B1 | P9T-E | Human | Esophagus | ESCC | 2.12e-06 | 5.85e-01 | 0.1131 |
| 1545 | CYP1B1 | P47T-E | Human | Esophagus | ESCC | 1.14e-03 | 2.65e-01 | 0.1067 |
| 1545 | CYP1B1 | P62T-E | Human | Esophagus | ESCC | 2.43e-11 | 7.02e-01 | 0.1302 |
| 1545 | CYP1B1 | P107T-E | Human | Esophagus | ESCC | 1.15e-07 | 4.89e-01 | 0.171 |
| 1545 | CYP1B1 | P130T-E | Human | Esophagus | ESCC | 2.91e-26 | 1.13e+00 | 0.1676 |
| 1545 | CYP1B1 | P5_S10_cSCC | Human | Skin | cSCC | 1.58e-08 | -3.32e-01 | -0.299 |
| 1545 | CYP1B1 | P2_cSCC | Human | Skin | cSCC | 9.16e-11 | 1.03e+00 | -0.024 |
| 1545 | CYP1B1 | cSCC_p1 | Human | Skin | cSCC | 3.98e-12 | -3.54e-01 | -0.1916 |
| 1545 | CYP1B1 | cSCC_p10 | Human | Skin | cSCC | 1.95e-05 | -3.17e-01 | -0.2095 |
| 1545 | CYP1B1 | cSCC_p11 | Human | Skin | cSCC | 8.14e-13 | -3.54e-01 | -0.2102 |
| 1545 | CYP1B1 | cSCC_p7 | Human | Skin | cSCC | 2.04e-10 | -3.44e-01 | -0.2332 |
| 1545 | CYP1B1 | cSCC_p8 | Human | Skin | cSCC | 1.55e-09 | -3.37e-01 | -0.1971 |
| 1545 | CYP1B1 | cSCC_p9 | Human | Skin | cSCC | 5.40e-11 | -3.50e-01 | -0.1991 |
| 1545 | CYP1B1 | male-WTA | Human | Thyroid | PTC | 9.44e-26 | 4.72e-01 | 0.1037 |
| 1545 | CYP1B1 | PTC01 | Human | Thyroid | PTC | 5.33e-41 | 1.51e+00 | 0.1899 |
| 1545 | CYP1B1 | PTC05 | Human | Thyroid | PTC | 4.48e-20 | 1.24e+00 | 0.2065 |
| 1545 | CYP1B1 | PTC06 | Human | Thyroid | PTC | 1.28e-75 | 3.09e+00 | 0.2057 |
| 1545 | CYP1B1 | PTC07 | Human | Thyroid | PTC | 1.12e-39 | 1.07e+00 | 0.2044 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
| GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
| GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
| GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
| GO:0000302111 | Esophagus | ESCC | response to reactive oxygen species | 150/8552 | 222/18723 | 3.06e-11 | 1.02e-09 | 150 |
| GO:0042542111 | Esophagus | ESCC | response to hydrogen peroxide | 102/8552 | 146/18723 | 2.64e-09 | 5.81e-08 | 102 |
| GO:0008631110 | Esophagus | ESCC | intrinsic apoptotic signaling pathway in response to oxidative stress | 38/8552 | 45/18723 | 8.42e-08 | 1.43e-06 | 38 |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:003461420 | Esophagus | ESCC | cellular response to reactive oxygen species | 103/8552 | 155/18723 | 1.34e-07 | 2.17e-06 | 103 |
| GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
| GO:00703018 | Esophagus | ESCC | cellular response to hydrogen peroxide | 68/8552 | 98/18723 | 1.70e-06 | 2.03e-05 | 68 |
| GO:200037718 | Esophagus | ESCC | regulation of reactive oxygen species metabolic process | 100/8552 | 157/18723 | 3.87e-06 | 4.17e-05 | 100 |
| GO:00060668 | Esophagus | ESCC | alcohol metabolic process | 202/8552 | 353/18723 | 7.32e-06 | 7.26e-05 | 202 |
| GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
| GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
| GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
| GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
| GO:007259318 | Esophagus | ESCC | reactive oxygen species metabolic process | 137/8552 | 239/18723 | 1.82e-04 | 1.16e-03 | 137 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
| hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYP1B1 | SNV | Missense_Mutation | novel | c.7A>C | p.Thr3Pro | p.T3P | Q16678 | protein_coding | deleterious_low_confidence(0.01) | benign(0.193) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| CYP1B1 | SNV | Missense_Mutation | novel | c.5G>C | p.Gly2Ala | p.G2A | Q16678 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| CYP1B1 | SNV | Missense_Mutation | c.1444C>G | p.Leu482Val | p.L482V | Q16678 | protein_coding | deleterious(0.04) | possibly_damaging(0.744) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CYP1B1 | SNV | Missense_Mutation | rs201181935 | c.1290N>G | p.Asp430Glu | p.D430E | Q16678 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CYP1B1 | SNV | Missense_Mutation | novel | c.191N>A | p.Ala64Glu | p.A64E | Q16678 | protein_coding | deleterious(0.04) | possibly_damaging(0.815) | TCGA-BH-A0DQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| CYP1B1 | SNV | Missense_Mutation | novel | c.440N>T | p.Ala147Val | p.A147V | Q16678 | protein_coding | tolerated(0.92) | benign(0.006) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
| CYP1B1 | SNV | Missense_Mutation | novel | c.1250A>G | p.Asp417Gly | p.D417G | Q16678 | protein_coding | tolerated(0.12) | benign(0.229) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CYP1B1 | SNV | Missense_Mutation | novel | c.245G>A | p.Gly82Asp | p.G82D | Q16678 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CYP1B1 | SNV | Missense_Mutation | c.776N>A | p.Arg259His | p.R259H | Q16678 | protein_coding | deleterious(0.01) | probably_damaging(0.952) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| CYP1B1 | SNV | Missense_Mutation | c.312N>A | p.His104Gln | p.H104Q | Q16678 | protein_coding | deleterious(0.01) | benign(0.157) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | AMINOGLUTETHIMIDE | AMINOGLUTETHIMIDE | 18256205 | |
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | ANASTROZOLE | ANASTROZOLE | 18256205 | |
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | FORMESTANE | FORMESTANE | 18256205 | |
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | paclitaxel | PACLITAXEL | 21151855,24599932 | |
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | ADJUVANT | 7787697 | ||
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | fluorouracil | FLUOROURACIL | 24958282 | |
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | PINOCEMBRIN | PINOCEMBRIN | ||
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | docetaxel | DOCETAXEL | 21151855 | |
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | FADROZOLE | FADROZOLE | 18256205 | |
| 1545 | CYP1B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450, CLINICALLY ACTIONABLE | TOREMIFENE | TOREMIFENE | 8262671 |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |